Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIGOR: Vorasidenib Maintenance in IDH-mutant Grade 2 or 3 Astrocytoma
NCT06809322Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2026
- Primary completion
- Apr 2035
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, triple-blind trial of vorasidenib in astrocytoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival at 10.5 years. Started Jan 2026; status: recruiting.
02
Drugs
vorasidenib
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT06809322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809322.